Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2206-2223

  Goldhirsch, A ^a,av   Winer, E P ^b   Coates, A S ^c   Gelber, R D ^b   Piccart Gebhart, M ^d   Thurlimann B ^e   Senn, H J ^f   Albain, Kathy S ^g   André, Fabrice ^h   Bergh, Jonas ⁱ   Bonnefoi, Hervé ^j   Bretel Morales, Denisse ^k   Burstein, Harold ^l   Cardoso, Fatima ^m   Castiglione Gertsch, Monica ⁿ   Coates, Alan S ^c   Colleoni, Marco ^a   Costa, Alberto ^o,au   Curigliano, Giuseppe ^a   Davidson, Nancy E ^p   Leo, Angelo Di ^q   Ejlertsen, Bent ^r   Forbes, John F ^s   Gelber, Richard D ^l   Gnant, Michael ^t   Goodwin, Pamela ^u   Goss, Paul E ^v   Harris, Jay R ^w   Hayes, Daniel F ^x   Hudis, Clifford A ^y   Ingle, James N ^z   Jassem, Jacek ^aa   Jiang, Zefei ^ab   Karlsson, Per ^ac   Loibl, Sibylle ^ad   Morrow, Monica ^ae   Namer, Moise ^af   Osborne, C Kent ^ag   Partridge, Ann H ^b   Penault Llorca, Frédérique ^ah   Perou, Charles M ^ai   Pritchard, Kathleen I ^aj   Rutgers, Emiel J T ^ak   Sedlmayer, Felix ^al   Semiglazov, Vladimir ^am   Shao, Zhi Ming ^an   Smith, Ian ^ao   Thürlimann, Beat ^e   Toi, Masakazu ^ap   Tutt, Andrew ^aq   Untch, Michael ^ar   Viale, Giuseppe ^a   Watanabe, Toru ^as   Wilcken, Nicholas ^c   Winer, Eric P ^l   Wood, William C ^at   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d JULES BORDET INSTITUTE   (Belgium)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Tumor Center ZeTuP   (Switzerland)

^g LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITÉ DE BORDEAUX   (France)

^k GECOPERU   (Peru)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m Champalimaud Cancer Center   (Portugal)

ⁿ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^o EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^p UNIVERSITY OF PITTSBURGH   (United States)

^q HOSPITAL OF PRATO   (Italy)

^r International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^s UNIVERSITY OF NEWCASTLE   (Australia)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u MOUNT SINAI HOSPITAL   (Canada)

^v MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^w BRIGHAM AND WOMEN S HOSPITAL   (United States)

^x UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^y WEILL CORNELL MEDICAL COLLEGE   (United States)

^z MAYO CLINIC CANCER CENTER   (United States)

^aa MEDICAL UNIVERSITY OF GDANSK   (Poland)

^ab BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^ac SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ad German Breast Group   (Germany)

^ae MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^af CENTRE ANTOINE LACASSAGNE   (France)

^ag BAYLOR COLLEGE OF MEDICINE   (United States)

^ah Center Jean Perrin   (France)

^ai UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^aj UNIVERSITY OF TORONTO   (Canada)

^ak NETHERLANDS CANCER INSTITUTE   (Netherlands)

^al PARACELSUS MEDICAL UNIVERSITY   (Austria)

^am N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^an FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^ao INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^ap KYOTO UNIVERSITY HOSPITAL   (Japan)

^aq GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^ar UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^as Hamamatsu Oncology Center   (Japan)

^at EMORY UNIVERSITY   (United States)

^au REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^av Ospedale Italiano   (Switzerland)

more..

Author keywords

Early breast cancer; Radiation therapy; St Gallen consensus; Subtypes; Surgery; Systemic adjuvant therapies

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BYL 719; CANCER VACCINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; FULVESTRANT; GDC 0032; GONADORELIN AGONIST; IPILIMUMAB; KI 67 ANTIGEN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TENASCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CALCIFICATION; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CLINICAL DECISION MAKING; COMORBIDITY; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG POTENTIATION; DRUG TARGETING; EARLY CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; HEREDITY; HISTOPATHOLOGY; HUMAN; LIFESTYLE; LUMINAL A DISEASE; LUMINAL B DISEASE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MEDITERRANEAN DIET; METRONOMIC DRUG ADMINISTRATION; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; OBESITY; ONCOGENE; ONCOGENE NEU; ONCOGENE TP53; PARTIAL MASTECTOMY; PATIENT CARE; PATIENT PREFERENCE; PATIENT SAFETY; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PLURIPOTENT STEM CELL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; SIGNAL TRANSDUCTION; SOCIAL ASPECT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EARLY BREAST CANCER; RADIATION THERAPY; ST GALLEN CONSENSUS; SUBTYPES; SURGERY; SYSTEMIC ADJUVANT THERAPIES;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MASTECTOMY; RECEPTOR, ERBB-2;

EID: 84883325272     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt303     Document Type: Article

References (119)

1. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
3. Dunbier AK, Anderson H, Ghazoui Z, et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids 2011; 76: 736-740.
4. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
5. Galimberti V, Botteri E, Chifu C, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. Breast Cancer Res Treat 2012; 131: 819-825.
6. Martelli G. Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg 2012; 256: 920-924.
7. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet 2013 July 18 [epub ahead of print], doi: 10.1016/S0140-6736(13)61094-6.
8. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013; 14: 741-748.
9. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381: 805-816.
10. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausalhormonereceptor- positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
11. Osborne CK, SchiffR. Overcoming resistance to endocrine therapy due to PI3K/AKT pathway activation by combinations of mTOR, AKT or MEK inhibitors. The Breast 2013; 22(Supp 1); S2 (Abstr. SP1.04).
12. Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K Inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition. Cancer Discov 2012; 2: 1036-1047.
13. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2: 1048-1063.
14. Varna M, Bousquet G, Plassa LF, et al. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011 May 9 [epub ahead of print], doi: 10.1155/2011/284584.
15. Jackson JG, Pant V, Li Q, et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21: 793-806.
16. Bailey ST, Shin H, Westerling T, et al. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA 2012; 109: 18060-5.
17. Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 Status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12: 527-539.
18. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012;379: 432-444.
19. Di Leo A. The continued evidence from overviews: what is the clinical utility? The Breast 2013; 22(Supp 1); S2 (Abstr. SP1.02).
20. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013; 3: 27-34.
21. Hayes DF. From the genome to bedside: are we lost in translation?. The Breast 2013; 22(Supp 1); S3 (Abstr. SP2.02).
22. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
23. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
24. Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31: 203-209.
25. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 2011; 103: 1656-1664.
26. Nielsen TO, Polley M-YC, Leung SCY, et al. An international Ki-67 reproducibility study. In Presented at the 35th San Antonio Breast Cancer Symposium, December 4-8, 2012 (Abstr S4-6).
27. Luporsi E, Andre F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915.
28. Buckland G, Travier N, Cottet V, et al. Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. Int J Cancer 2013; 132: 2918-2927.
29. Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and recurrence. The Breast 2013; 22(Supp 1); S5. (Abstr. SP3.01).
30. Folkerd EJ, Dixon JM, Renshaw L, et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 2012; 30: 2977-2980.
31. Dowsett M, Folkerd E. Sex hormones and breast cancer risk and prognosis. The Breast 2013; 22(Supp 1); S5. (Abstr. SP3.02).
32. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-147.
33. Niraula S, Ocana A, Ennis M, et al. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 2012; 134: 769-781.
34. Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010; 28: 3411-3415.
35. Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial. J Clin Oncol 2012; 30: 3967-3975.
36. Goodwin PJ, Pritchard KI. Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 2010; 28: 3405-3407.
37. Pfeiler G, Koenigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29: 2653-2659.
38. Bertolini F. Adipose tissue and breast cancer progression: a link between metabolism and cancer. The Breast 2013; 22(Supp 1); S6 (Abstr. SP4.01).
39. Bertolini F, Lohsiriwat V, Petit JY, et al. Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons. Biochim Biophys Acta 2012; 1826: 209-214.
40. Petit JY, Botteri E, Lohsiriwat V, et al. Locoregional recurrence risk after lipofilling in breast cancer patients. Ann Oncol 2012; 23: 582-588.
41. Oskarsson T, Acharyya S, Zhang XH, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867-874.
42. Oskarsson T. Extracellular matrix players in breast cancer progression and metastasis. The Breast 2013; 22(Supp 1); S7 (Abstr. SP4.04).
43. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
44. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
45. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 2011; 12: 631-641.
46. Goldhirsch A. Personalized adjuvant therapies: lessons from the past. The Breast 2013; 22(Supp 1); S1 (Abstr. SP0.01).
47. Kerbel RS. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis. The Breast 2013; 22(Supp 1); S7. (Abstr. SP4.03)(manuscript in preparation).
48. Hassett MJ, Silver SM, Hughes ME, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012; 30: 2218-2226.
49. Drukker CA, Bueno-de-Mesquita JM, Retel VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 131: 929-936.
50. Pusztai L. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. The Breast 2013; 22(Supp 1); S9 (Abstr. SP5.03).
51. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
52. Dubsky P, Filipits M, Jakesz R, et al. Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013; 24: 640-647.
53. Sgroi D, Sestak I, Cuzick J, et al. Comparative performance of breast cancer index (BCI) versus oncotype DX and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node negative breast cancer patients: a transATAC study. In Presented at the 35th San Antonio Breast Cancer Symposium, December 4-8, 2012 (Abstr S1-9).
54. Viale G. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. The Breast 2013; 22(Supp 1); S9 (Abstr. SP5.04).
55. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
56. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
57. Andre F. Risk stratification for treatment choice: opportunities, challenges and tools. The Breast 2013; 22(Supp 1); S10 (Abstr. SP6.01).
58. Sotiriou C. Immune signatures: prognostic and predictive role in breast cancer. The Breast 2013; 22(Supp 1); S11 (Abstr. SP6.04).
59. Curigliano G. Developing an effective breast cancer vaccine. The Breast 2013; 22(Supp 1); S10 (Abstr. SP6.02)(manuscript in preparation).
60. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
61. Morrow M. Personalizing extent of breast cancer surgery according to molecular subtypes. The Breast 2013; 22(Supp 1); S12 (Abstr. SP7.03).
62. Kiess AP, McArthur HL, Mahoney K, et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 2012; 118: 1982-1988.
63. Rutgers E. Who should not undergo breast conservation? The Breast 2013;22 (Supp 1); S13 (Abstr. SP7.04).
64. Wood WC. Close/positive margins after breast-conserving therapy. The Breast 2013; 22(Supp 1); S13 (Abstr. SP7.05).
65. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297-305.
66. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569-575.
67. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node versus observation after axillary UltraSouND). Breast 2012; 21: 678-681.
68. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520.
69. Yarnold JR. The UK START (standardisation of breast radiotherapy) trials: 10-year follow-up results. In Presented at the 35th San Antonio Breast Cancer Symposium, December 4-8, 2012 (Abstr. S4-1).
70. Harris JR. Hypofractionation in the era of modulated radiotherapy. The Breast 2013; 22(Supp 1); S14 (Abstr. SP8.02).
71. Orecchia R. Partial breast irradiation: targeting volume or breast molecular subtypes? The Breast 2013; 22(Supp 1); S14 (Abstr. SP8.01).
72. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74: 987-1001.
73. Polgar C, Van limbergen E, Potter R, et al. Patient selection for accelerated partialbreast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94: 264-273.
74. Sedlmayer F. Partial breast re-irradiation for local recurrence of breast carcinoma: benefit and potential long term side effects. The Breast 2013; 22(Supp 1); S15 (Abstr. SP8.04).
75. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
76. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
77. Cheang MC, Voduc KD, Tu D, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012; 18: 2402-2412.
78. Burstein HJ. Patients with triple-negative breast cancer: is there an optimal adjuvant treatment?. The Breast 2013; 22(Supp 1); S16 (Abstr. SP9.02).
79. Colleoni M. Extended adjuvant chemotherapy in endocrine non-responsive disease. The Breast 2013; 22(Supp 1); S17 (Abstr. SP10.01).
80. von Minckwitz G. Selecting the neoadjuvant treatment by molecular subtype: how to maximise the benefit. The Breast 2013; 22(Supp 1); S16 (Abstr. SP9.03).
81. Gianni L. Zambetti M, Clark K, et al. Gene expression profiles in paraffinembedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
82. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119: 551-558.
83. Piccart M. Patients with HER2 positive breast cancer: delivery, duration and combination therapies. The Breast 2013; 22(Supp 1); S16 (Abstr. SP9.04).
84. Davidson NE. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. The Breast 2013; 22(Supp 1); S18 (Abstr. SP10.02).
85. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
86. Goss PE, Ingle JN, Martino S, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 2013; 24: 355-361.
87. Ingle JN. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. The Breast 2013; 22 (Supp 1); S19 (Abstr. SP10.05).
88. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103: 1299-1309.
89. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 2012; 104: 1094-1101.
90. Loibl S, Jackisch C, Gade S. Neoadjuvant chemotherapy in the very young, 35 years of age or younger. In Presented at the 35th San Antonio Breast Cancer Symposium, December 4-8, 2012 (Abstr. S3-1).
91. Partridge AH. Management of breast cancer in the very young. The Breast 2013; 22(Supp 1); S18 (Abstr. SP10.04).
92. Smith I. Follow-up tests to detect recurrent disease: patient's reassurance or medical need? The Breast 2013; 22(Supp 1); S17 (Abstr. SP9.05).
93. Hayes DF. Targeting adjuvant chemotherapy: a good idea that needs to be proven. J Clin Oncol 2012; 30: 1264-1267.
94. Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal A breast cancer?. J Clin Oncol 2012; 30: 1260-1263.
95. Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23: 2866-2873.
96. Regan MM, Pagani O, Walley B, et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008; 19: 1231-1241.
97. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
98. Reed SD, Dinan MA, Schulman KA, et al. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med 2013; 15: 203-211.
99. Vanderlaan BF, Broder MS, Chang EY, et al. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. Am J Manag Care 2011; 17: 455-464.
100. Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene recurrence score(R) assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer 2013 April 20 [epub ahead of print], doi: 10.1016/j.ejca.2013.03.009.
101. Hannouf MB, Xie B, Brackstone M, et al. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with earlystage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer. BMC Cancer 2012; 12: 447.
102. Lamond NW, Skedgel C, Rayson D, et al. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 2012; 133: 1115-1123.
103. Tsoi DT, Inoue M, Kelly CM, et al. Cost-effectiveness analysis of recurrence scoreguided treatment using a 21-gene assay in early breast cancer. Oncologist 2010; 15: 457-465.
104. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005; 11: 313-324.
105. Klang SH, Hammerman A, Liebermann N, et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed healthcare organization. Value Health 2010; 13: 381-387.
106. Hall PS, McCabe C, Stein RC, et al. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 2012; 104: 56-66.
107. Blohmer JU, Rezai M, Kummel S, et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a costeffectiveness evaluation in the German setting. J Med Econ 2013; 16: 30-40.
108. Eiermann W, Rezai M, Kummel S, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013; 24: 618-624.
109. Kondo M, Hoshi SL, Ishiguro H, et al. Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph nodenegative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat 2012; 133: 759-768.
110. Sahin AA, Ro J, Ro JY, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma: significant correlation with prognosis. Cancer 1991;68: 549-557.
111. Railo M, Lundin J, Haglund C, et al. Ki-67, p53, ER-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997; 36: 369-374.
112. Jansen RL, Hupperets PS, Arends JW, et al. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 1998; 78: 460-465.
113. Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10-26.
114. Trihia H, Murray S, Price K, et al. Ki-67 expression in breast carcinoma. Cancer 2003; 97: 1321-1331.
115. de Azambuja E, Cardoso F, de CG, Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504-1513.
116. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-170.
117. Viale G, Regan MM, Mastropasqua MG, et al. Value of Ki-67 in two randomized trials of adjuvant chemo-endocrine therapies for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212.
118. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26: 5569-5575.
119. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early stage breast cancer. N Engl J Med 2009; 360: 2055-2065.